The first outcome of the Optibrium and BioPharmics collaboration will be a new module for StarDrop, Optibrium’s small molecule design, optimisation and analysis software,. The new Surflex eSim 3D module, planned for the third quarter of 2021, will leverage BioPharmics’ three-dimensional (3D) ligand-based design approaches, offering exceptional virtual screening and compound design capabilities for targets without available 3D structure information.
BioPharmics develops algorithms and software for computational drug design. In studies, BioPharmics says its technology is able to predict active ligand conformations starting from known actives, even in the absence of 3D structure information for ligands or target.
Optibrium develops comprehensive solutions and deep learning methods for computational drug discovery. The collaboration with Biopharmics will greatly enhance StarDrop’s capabilities for 3D ligand-based design, extending its range of in silico modelling and de novo design features.
